Indications

Non-Hodgkin’s Lymphoma (NHL)

RIABNI^® (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI^®, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

BEHIND RIABNI^® ANSWERING THE GROWING NEED FOR BIOSIMILARS

Amgen is a leader in biologics with a growing portfolio in biosimilars.

HERITAGE

THE HEALTHCARE COMMUNITY HAS BEEN ABLE TO TRUST US FOR DECADES

AT AMGEN, WE’RE COMMITTED TO DELIVERING QUALITY PRODUCTS TO EVERY PATIENT, EVERY TIME
Expertise
REAL-WORLD EXPERIENCE AND EXPERTISE PAVED THE WAY FOR OUR LEADERSHIP IN BIOSIMILARS
- *Available biosimilars across all global markets.
Commitment

WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO DEVELOPING THE BIOSIMILAR MARKETPLACE

Invested in the development of biosimilars and novel therapeutics

OUR BIOSIMILAR PIPELINE IS TARGETED TO ADDRESS THE GREATEST TREATMENT NEEDS WITHOUT COMPROMISING HIGH-LEVEL CUSTOMER SERVICE^1-5
Support

WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES